drugset / Trial / NCT06221683

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

NCT06221683

Phase 2 Recruiting 500 enrolled Children's Hospital of Soochow University
Non-randomizedFactorialOpen-labelTreatment

Summary

The goal of this clinical trial is to estimate the rate (probability) of complete remission or complete remission with incomplete count recovery (CR/CRi) with negative MRD after induction I and II, event-free survival (EFS), and cumulative incidence (probability) of relapse (CIR), in patients receiving molecular/precision medicine and MRD-driven remission inductions, and to assess secondarily if there is an improvement over the AML2018 protocol.

Timeline

Start
2024-01-01
Primary completion
2028-12
Completion
2029-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Avapritinib Small molecule 1.65 mg/kg
Subject Avapritinib Small molecule 50 mg/m2
Subject Cytarabine Small molecule 0.33 mg/kg Intravenous
Subject Cytarabine Small molecule 3.3 mg/kg Intravenous
Subject Cytarabine Small molecule 10 mg/m2 Intravenous
Subject Cytarabine Small molecule 100 mg/m2 Intravenous
Subject Etoposide Small molecule 3.3 mg/kg Intravenous
Subject Etoposide Small molecule 100 mg/m2 Intravenous
Subject Gilteritinib Small molecule 0.7 mg/kg
Subject Gilteritinib Small molecule 20 mg/m2
Subject Homoharringtonine Small molecule 0.1 mg/kg Intravenous
Subject Homoharringtonine Small molecule 3 mg/m2 Intravenous
Subject Idarubicin Small molecule 0.1 mg/kg Intravenous
Subject Idarubicin Small molecule 3 mg/m2 Intravenous
Subject Mitoxantrone hydrochloride liposome Unknown 0.17 mg/kg Intravenous
Subject Mitoxantrone hydrochloride liposome Unknown 5 mg/m2 Intravenous
Subject Sorafenib Small molecule 3.3 mg/kg
Subject Sorafenib Small molecule 100 mg/m2
Subject Venetoclax Small molecule 3.33 mg/kg
Subject Venetoclax Small molecule 100 mg/m2
Background filgrastim Protein / enzyme biologic 5 ug/kg Subcutaneous